Pastores GM - Search Results

1

Enzyme replacement therapy for Anderson-Fabry disease.

El Dib RP, Pastores GM. El Dib RP, et al. Among authors: pastores gm. Cochrane Database Syst Rev. 2010 May 12;(5):CD006663. doi: 10.1002/14651858.CD006663.pub2. Cochrane Database Syst Rev. 2010. Update in: Cochrane Database Syst Rev. 2013 Feb 28;(2):CD006663. doi: 10.1002/14651858.CD006663.pub3 PMID: 20464743 Updated. Review.

2

Enzyme replacement therapy for Anderson-Fabry disease.

El Dib RP, Nascimento P, Pastores GM. El Dib RP, et al. Among authors: pastores gm. Cochrane Database Syst Rev. 2013 Feb 28;(2):CD006663. doi: 10.1002/14651858.CD006663.pub3. Cochrane Database Syst Rev. 2013. Update in: Cochrane Database Syst Rev. 2016 Jul 25;7:CD006663. doi: 10.1002/14651858.CD006663.pub4 PMID: 23450571 Updated. Review.

3

A systematic review of new advances in the management of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): focus on galsulfase.

El Dib RP, Pastores GM. El Dib RP, et al. Among authors: pastores gm. Biologics. 2009;3:459-68. doi: 10.2147/btt.2009.3580. Epub 2009 Oct 12. Biologics. 2009. PMID: 19851471 Free PMC article.

4

Laronidase for treating mucopolysaccharidosis type I.

El Dib RP, Pastores GM. El Dib RP, et al. Among authors: pastores gm. Genet Mol Res. 2007 Sep 30;6(3):667-74. Genet Mol Res. 2007. PMID: 18050087 Free article. Review.

5

Effects of enzyme replacement therapy in Fabry disease--a comprehensive review of the medical literature.

Lidove O, West ML, Pintos-Morell G, Reisin R, Nicholls K, Figuera LE, Parini R, Carvalho LR, Kampmann C, Pastores GM, Mehta A. Lidove O, et al. Among authors: pastores gm. Genet Med. 2010 Nov;12(11):668-79. doi: 10.1097/GIM.0b013e3181f13b75. Genet Med. 2010. PMID: 20962662 Free article. Review.

6

Advances in the management of Anderson-Fabry disease: enzyme replacement therapy.

Pastores GM, Thadhani R. Pastores GM, et al. Expert Opin Biol Ther. 2002 Mar;2(3):325-33. doi: 10.1517/14712598.2.3.325. Expert Opin Biol Ther. 2002. PMID: 11890871 Review.

7

Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease.

Pastores GM, Boyd E, Crandall K, Whelan A, Piersall L, Barnett N. Pastores GM, et al. Nephrol Dial Transplant. 2007 Jul;22(7):1920-5. doi: 10.1093/ndt/gfm096. Epub 2007 Mar 29. Nephrol Dial Transplant. 2007. PMID: 17395657 Clinical Trial.

8

Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease.

Schiffmann R, Martin RA, Reimschisel T, Johnson K, Castaneda V, Lien YH, Pastores GM, Kampmann C, Ries M, Clarke JT. Schiffmann R, et al. Among authors: pastores gm. J Pediatr. 2010 May;156(5):832-7, 837.e1. doi: 10.1016/j.jpeds.2009.11.007. Epub 2010 Jan 25. J Pediatr. 2010. PMID: 20097359 Clinical Trial.

9

To see a world in a grain of sand: elucidating the pathophysiology of Anderson-Fabry disease through investigations of a cellular model.

Pastores GM, Hughes DA. Pastores GM, et al. Kidney Int. 2009 Feb;75(4):351-3. doi: 10.1038/ki.2008.606. Kidney Int. 2009. PMID: 19180148 Free article.

10

Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta.

Mehta A, Beck M, Kampmann C, Frustaci A, Germain DP, Pastores GM, Sunder-Plassmann G. Mehta A, et al. Among authors: pastores gm. Mol Genet Metab. 2008 Sep-Oct;95(1-2):114-5. doi: 10.1016/j.ymgme.2008.07.002. Epub 2008 Aug 12. Mol Genet Metab. 2008. PMID: 18701330 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

202 results

Search Page

Filters